![Poster area_05](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/poster-area_05/9433770-1-eng-GB/poster-area_05_i770.jpg)
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required